Endogenex emphasizes the 48-week clinical regent 1 study

Minneapolis, May 03, 2025 (Globe Newswire) -Endogenex, a company for medical devices at clinical level that is devoted to improving the results of people with type 2-diabetes (T2D), showed significant results from his clinical study by Regent-1 Australia at digestive Disease Week (DDW) 2025 in San Diego.

Regent-1 examined the safety and feasibility of the endogenous electrical field system (the recet system) in the USA and Australia. The recet system is an examining, endoscopic outpatient process that does not use thermal energy to treat the inflamed and dysfunctional tissue, which is associated with type 2 duodenopathy of type 2. Treatment regenerates healthy cells in the mucous membrane and sub-mucosal layers of the duodenal-intestine-dem upper part of the small intestine, in which metabolic coordination occurs.

The results of the Regent 1 Australia study showed significant improvements in insulin sensitivity and beta cell function after 12 weeks. The improvement lasted after 48 weeks in an energy dose, which indicates a durability of the treatment effect. In 100% of the cases, procedural success was achieved without serious undesirable events or procedural events related to the procedure.

“This first-class study shows that a non-thermal electrical energy treatment of the duodenum of the physiological core mechanisms on which type 2 diabetes can be used, significantly and durlal: especially insulin resistance and beta cell function,” said Dr. Richard Pratley, Medical Director of the Adventure High Diabetes Institute; and Senior Investigator and Diabetes Program Lead, Adventhealth Translational Research Institute in Orlando, Fl. “The results are promising for millions of people who are looking for new approaches with type -2 -diabetes life to improve their metabolic health.”

“These results reinforce that the duodenum mucosa and submucosa are critical therapeutic goals for the further development of type 2 diabetes treatment and disease management,” said Dr. Barham K. Abu Dayyeh, senior author of the Regent 1 study. “These results are the basis for further studies and we strive to expand the clinical evidence base.”

“The Regent 1 study continues to provide promising results and strengthens the potential of the recet system as a transformative treatment for type 2 diabetes,” said Stacey Pugh, CEO from endogenex. “We have been knowing for some time that the duodenum plays an important role in type 2 diabetes, and these new data together with other state-of-the-art analyzes that are presented here at DDW and reinforce the duoden as a new goal in the treatment of type 2 diabetes.”

About DDW

The digestive Disease Week® (DDW) is the largest international meeting of doctors, researchers and academics in the areas of gastroenterology, hepatology, endoscopy and stomach surgery. Together from the American Association for the Study of Leber Diseases (AASLD), the American Mastroenterological Association (AGA), the American Society for Mastrointestinal Endoscopy (ASGE) and the Society for Operation of the Clotary Tract (SSAT), DDW are a personnel and online meeting from the 3rd. May. GI -research, medicine and technology. You can find more information at www.ddw.org.

Via endogenex ™

Endoogenex was founded in cooperation with the Mayo clinic and pioneering work for type -2 -diabetes, which research now indicates as a likely cause: a damaged duodenum. The new, outpatient endoscopic process of the company uses non-thermal pulsed electrical fields (PEF) to treat inflamed and dysfunctional tissue, which is connected to the diabetic duodenopathy of type 2 diabetics. A specialized endogenex catheter delivers PEF to the mucous membrane and the duodenal fabric of Sub-Mucosa, which initiates the natural process of cell regeneration of the body. Our goal is to restore the intestine in a healthier state so that we can overcome the patient more than just their symptoms – and potentially slow or even their progression of the disease. If we follow science in the intestine, we hope to redefine what is possible for diabetes care.

For more information – including the RECET study, which is currently registering new patients, please visit www.endogenex.com and www.retstudy.com.

Media inquiries:

Ashley Biladeau
Biladeau advice for endogenex
ashley@biladauconsulting.com

Krissy Wright
Chief Financial Officer
kwright@endogenex.com